Genmab A/S (NASDAQ:GMAB) Sets New 1-Year Low – What’s Next?

Genmab A/S (NASDAQ:GMAB)’s stock price hit a new 52-week low on Wednesday . The stock traded as low as $18.62 and last traded at $18.66, with a volume of 1793889 shares. The stock had previously closed at $19.58.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Truist Financial decreased their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Stock Performance

The company has a market capitalization of $12.35 billion, a P/E ratio of 10.72, a P/E/G ratio of 2.65 and a beta of 0.98. The business’s fifty day simple moving average is $20.81 and its 200-day simple moving average is $21.73.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GMAB. Deep Track Capital LP bought a new position in Genmab A/S during the fourth quarter valued at $41,740,000. Renaissance Technologies LLC raised its position in shares of Genmab A/S by 7.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock valued at $40,199,000 after buying an additional 139,722 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock valued at $35,612,000 after acquiring an additional 938,455 shares during the last quarter. Two Sigma Advisers LP grew its position in Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after acquiring an additional 1,038,400 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in Genmab A/S by 18.0% during the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock worth $34,316,000 after acquiring an additional 251,241 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.